Figure 2.

Subgroup analysis: change relative to the base case incremental cost-effectiveness ratio (ICER; discounted) in patient subgroups dichotomously stratified by baseline type 2 diabetes status, eGFR level, or urine albumin-creatinine ratio (UACR). The degree to which the ICER of the subgroup of interest increases or decreases relative to the ICER relating to the base case population receiving dapagliflozin with standard therapy versus standard therapy alone. QALY, quality-adjusted life year.